US FDA grants fast track designation to Dizal’s Birelentinib to treat relapsed/refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma

Dizal, a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the US Food and Drug Administration (FDA) has granted

To access the full article, please log in or subscribe.